Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-10

Fennec Pharmaceuticals (FENC)

CEO Jeffrey Hackman was paid $1,722,154 in fiscal year 2025, ↑ up 6.8% from fiscal year 2024, the 33rd percentile of its disclosed peer group (SEC filing 0001104659-26-050339 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,873,024
Robert Andrade total, FY2025
Chief Financial Officer — highest-paid officer; CEO Jeffrey Hackman: $1,722,154
33rd
CEO (Jeffrey Hackman) pay percentile vs peers
—
CEO-to-median pay ratio
98.29%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

FENC's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Robert Andrade$482,095$70,551$1,117,500$202,878$0$0$0$1,873,024
Chief Financial Officer
Jeffrey Hackman586,34345,833887,100202,8780001,722,154
Chief Executive Officer
Pierre Sayad464,0810311,0000000775,081
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Robert Andrade$1,873,024—$1,310,537—
Jeffrey Hackman1,722,1541,611,862—↑ +110,292
Pierre Sayad775,081483,506—↑ +291,575

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Fennec Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper FENC reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against FENC
1 company names FENC as a compensation peer

The list of companies that name FENC as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Pierre SayadChief Medical Officer$775,081
Jeffrey HackmanCEO$1,722,154
Robert AndradeCFO$1,873,024
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Dr. Jodi CookIndependent Director$153,715
Dr. Khalid IslamIndependent Director$214,019
Dr. Marco BrugheraIndependent Director$168,715
Mr. Chris A. RallisIndependent Director$173,715
Rosty RaykovIndependent Director—
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Dr. Khalid IslamOption25,0008.78—
Dr. Jodi CookOption20,0005.4—
Dr. Marco BrugheraOption20,0007.52—
Dr. Khalid IslamOption25,0004.26—
Mr. Chris A. RallisOption14,3442.44—
Mr. Chris A. RallisOption20,0005.1—
Mr. Chris A. RallisOption20,00010.93—
Mr. Chris A. RallisOption20,0008.78—
Mr. Chris A. RallisOption20,0004.26—
Mr. Chris A. RallisOption20,0006.17—
Mr. Chris A. RallisOption20,0007.52—
Mr. Chris A. RallisOption20,0005.59—
Mr. Chris A. RallisOption20,0005.58—
Mr. Chris A. RallisOption20,0007.88—
Dr. Khalid IslamOption25,0005.1—
Dr. Khalid IslamOption25,00010.93—
Dr. Khalid IslamOption25,0006.17—
Dr. Khalid IslamOption25,0007.52—
Dr. Khalid IslamOption25,0005.59—
Dr. Khalid IslamOption25,0005.58—
Dr. Khalid IslamOption25,0007.88—
Dr. Marco BrugheraOption35,5452.11—
Dr. Marco BrugheraOption20,0005.1—
Dr. Marco BrugheraOption20,00010.93—
Dr. Marco BrugheraOption20,0004.26—
Dr. Marco BrugheraOption20,0006.17—
Dr. Jodi CookOption20,0006.17—
Dr. Marco BrugheraOption20,0005.59—
Dr. Marco BrugheraOption20,0008.78—
Dr. Marco BrugheraOption20,0005.58—
Dr. Marco BrugheraOption20,0007.88—
Dr. Jodi CookOption20,0005.59—
Dr. Jodi CookOption20,0008.78—
Dr. Jodi CookOption20,0005.58—
Dr. Jodi CookOption20,0007.88—
Dr. Jodi CookOption20,0007.52—
05

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee seeks to attract and retain qualified and experienced individuals to Fennec's management team and motivate these individuals to perform to the best of their ability and in Fennec's best interests. The Committee considers compensation levels of comparable positions in similarly sized organizations in the biotechnology industry and utilizes various performance measures, including the advancement of product candidates and achievement of corporate objectives, to align executive compensation with performance.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1019,326,750336,060710,67798.29%Passed
20252025-06-0312,110,5981,595,423456,87088.36%Passed
20242024-06-259,830,484346,881294,14396.59%Passed
20232023-06-1215,855,506134,0255,08799.16%Passed
20222022-06-1412,812,365153,55052,05898.82%Passed
20212021-06-2913,354,125343,244148,56497.49%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1098.29%a
20252025-06-0388.36%b
20242024-06-2596.59%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Approved under the standard stated in the filing — “Abstentions will not be counted as votes for or against any proposal, and accordingly are not counted for purposes of determining the number of votes cast on any proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Dr. Khalid IslamIndependent · Board Chair · Audit$100,000$0$114,019——$214,019
Mr. Chris A. RallisIndependent · Audit (Chair)82,500091,215——173,715
Mr. RallisIndependent82,500091,215——173,715
Dr. Marco BrugheraIndependent · Audit77,500091,215——168,715
Dr. Jodi CookIndependent62,500091,215——153,715
Rosty RaykovIndependent · Not standing for re-election000——0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 15,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$405,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$405,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Fennec Pharmaceuticals2025Jeffrey Hackman$586,343$887,100$202,878$0$1,722,154

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Fennec Pharmaceuticals in fiscal 2025?
As disclosed, Robert Andrade (Chief Financial Officer) was the highest-paid executive at Fennec Pharmaceuticals in fiscal 2025, with total compensation of $1,873,024.
How does Fennec Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Jeffrey Hackman's total compensation ranked at the 33rd percentile of Fennec Pharmaceuticals's disclosed peer group.
How did shareholders vote on Fennec Pharmaceuticals's executive compensation?
As disclosed, 98.29% of shareholders supported Fennec Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Fennec Pharmaceuticals spend in total on board compensation for fiscal 2025?
As disclosed, Fennec Pharmaceuticals reported total board compensation of $405,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Robert AndradeDEF 14A2026-04-280001104659-26-050339Section “Executive Compensation”. As printed: 1,873,024. Filing ↗machine: r5 · c14 · span 447682–447691
2Section 01, Jeffrey HackmanDEF 14A2026-04-280001104659-26-050339Section “Executive Compensation”. As printed: 1,722,154. Filing ↗machine: r3 · c14 · span 439640–439649
3Section 01, Pierre SayadDEF 14A2026-04-280001104659-26-050339Section “Executive Compensation”. As printed: 775,081. Filing ↗machine: r7 · c14 · span 455995–456002
4Section 08, Dr. Khalid IslamDEF 14A2026-04-280001104659-26-050339Section “Director Compensation”. As printed: 214,019. Filing ↗machine: span 577047–577220
5Section 08, Mr. Chris A. RallisDEF 14A2026-04-280001104659-26-050339Section “Director Compensation”. As printed: 173,715. Filing ↗machine: span 586993–587166
6Section 08, Mr. RallisDEF 14A2026-04-280001104659-26-050339Section “Director Compensation”. As printed: 173,715. Filing ↗machine: span 586993–587166
7Section 08, Dr. Marco BrugheraDEF 14A2026-04-280001104659-26-050339Section “Director Compensation”. As printed: 168,715. Filing ↗machine: span 580358–580531
8Section 08, Dr. Jodi CookDEF 14A2026-04-280001104659-26-050339Section “Director Compensation”. As printed: 153,715. Filing ↗machine: span 583423–583596
9Section 08, Rosty RaykovDEF 14A2026-04-280001104659-26-050339Section “Director Compensation”. As printed: 0. Filing ↗
10Section 06, 2026 voteForm 8-K2026-06-100001104659-26-072425Item 5.07 · say-on-pay result. As reported: 98.29% (votes for as printed: 19,326,750). Filing ↗
11Section 06, 2025 voteForm 8-K2025-06-030001104659-25-055992Item 5.07 · say-on-pay result. As reported: 88.36% (votes for as printed: 12,110,598). Filing ↗
12Section 06, 2024 voteForm 8-K2024-06-250001104659-24-074748Item 5.07 · say-on-pay result. As reported: 96.59% (votes for as printed: 9,830,484). Filing ↗
13Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
14Section 09b board cost (computed)Computed——Cash 405,000 + equity 0 + all other 0 = 405,000, summed across the director compensation table rows.machine: formula: Σ = 405,000
15Fennec Pharmaceuticals (subject), Section 10b CEO totalDEF 14A2026-04-280001104659-26-050339CEO total compensation as printed in Fennec Pharmaceuticals's own proxy. As printed: 1,722,154. Filing ↗machine: r3 · c14 · span 439640–439649

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.